Prophylactic maintenance with venetoclax/azacitidine after reduced intensity conditioning allo-transplant for high risk MDS and AML

Jacqueline S. Garcia,Haesook T. Kim,H. Moses Murdock,Michela Ansuinelli,Jennifer Brock,Corey S. Cutler,Mahasweta Gooptu,Vincent T. Ho,John Koreth,Sarah Nikiforow,Rizwan Romee, Roman Shapiro,Daniel J. DeAngelo,Richard M. Stone, Denbaa Bat-Erdene,Jeremy Ryan, Manuel E. Contreras,Geoffrey Fell,Anthony Letai,Jerome Ritz, R Coleman Lindsley, Robert J Soiffer, Joseph H Antin

Blood advances（2024）

引用 0|浏览11

暂无评分

摘要

•Maintenance treatment was safe with low rates of infections and chronic GVHD, and minimal impact on T cell-immune reconstitution.•With 2-year follow-up, ven/aza maintenance showed a manageable safety profile and encouraging responses in high risk MDS/AML.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要